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adversary, are very much the forgotten man.
Corticosteroids reduce the numbers of eosinophils in blood and sputum by inhibiting the expression of pro-eosinophilic cytokines such as IL-5 and increase the rate of apoptosis and associated phagocytosis. It is known that titrating ICS against sputum eosinophils results in improved asthma control. 2 Whilst it is also known that sputum eosinophils correlate well with blood eosinophils, 3 the effects of increasing ICS dose on blood eosinophils are less well documented. 4 We therefore wanted to know whether ICS dose titration suppresses blood eosinophil counts in patients with persistent asthma.
In addition, we investigated whether leukotriene receptor antagonists (LTRA) have a similar effect when used as add-on therapy.
Another surrogate marker of Th2-mediated inflammation is exhaled breath nitric oxide (FeNO), where it has already been demonstrated that there is a dose-response effect of ICS. 5 We, therefore, performed a pooled analysis of our own studies performed by the Scottish Centre for Respiratory Research, where
we measured blood eosinophils and FeNO from a baseline of none or low-dose ICS to medium-dose ICS with or without LTRA. Fourteen studies were included in this analysis and are listed in Table 1 .
All were approved by the East of Scotland Regional Ethics Committee and registered at clinicaltrials.gov.
A total of 217 non-smoking patients with mild-moderate persis- In a retrospective observational cohort study, Price et al 9 demonstrated that those with eosinophils ≥400 cells/lL experience more severe exacerbations and have worse asthma control. The fundamental question therefore is whether ICS dose should be titrated against blood eosinophils as a surrogate inflammatory marker, especially given that pulmonary function shows a plateau in response above 400 lg/ day BDP equivalent dose. 10 In this regard, Green et al 2 showed that titrating ICS against sputum eosinophils resulted in significantly reduced exacerbations; whether the same outcome would be achieved by titrating against blood remains to be answered. We appreciate the limitations of our data, which were only short term, and we did not report any outcomes of asthma control. Furthermore, the observed effect might be due to possible systemic absorption from the lung, assessment of which would have required a surrogate marker of systemic cortisol suppression. Finally, our study lacks a placebo arm or a control arm with a fixed ICS dose, meaning we are unable to account for natural variation in blood eosinophils over time. In a more severe cohort of patients with asthma, it has been demonstrated for subjects who have an initial blood eosinophil count above 150 cells/ll, 85% of them remain above this value, even up to 56 weeks (based on four weekly blood eosinophil measurements).
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As we consider ever more complex anti-inflammatory therapies as the future of asthma care, we must not overlook inhaled corticos- 
